STING agonist-loaded mesoporous manganese-silica nanoparticles for vaccine applications. 2023

Cheng Xu, and Hannah E Dobson, and Mengjie Yu, and Wang Gong, and Xiaoqi Sun, and Kyung Soo Park, and Andrew Kennedy, and Xingwu Zhou, and Jin Xu, and Yao Xu, and Andrew W Tai, and Yu Leo Lei, and James J Moon
Department of Pharmaceutical Science, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.

Cyclic dinucleotides (CDNs), as one type of Stimulator of Interferon Genes (STING) pathway agonist, have shown promising results for eliciting immune responses against cancer and viral infection. However, the suboptimal drug-like properties of conventional CDNs, including their short in vivo half-life and poor cellular permeability, compromise their therapeutic efficacy. In this study, we have developed a manganese-silica nanoplatform (MnOx@HMSN) that enhances the adjuvant effects of CDN by achieving synergy with Mn2+ for vaccination against cancer and SARS-CoV-2. MnOx@HMSN with large mesopores were efficiently co-loaded with CDN and peptide/protein antigens. MnOx@HMSN(CDA) amplified the activation of the STING pathway and enhanced the production of type-I interferons and other proinflammatory cytokines from dendritic cells. MnOx@HMSN(CDA) carrying cancer neoantigens elicited robust antitumor T-cell immunity with therapeutic efficacy in two different murine tumor models. Furthermore, MnOx@HMSN(CDA) loaded with SARS-CoV-2 antigen achieved strong and durable (up to one year) humoral immune responses with neutralizing capability. These results demonstrate that MnOx@HMSN(CDA) is a versatile nanoplatform for vaccine applications.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008345 Manganese A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035)
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012822 Silicon Dioxide Transparent, tasteless crystals found in nature as agate, amethyst, chalcedony, cristobalite, flint, sand, QUARTZ, and tridymite. The compound is insoluble in water or acids except hydrofluoric acid. Silica,Aerosil,Aerosil 380,Cristobalite,Quso G-32,Quso G32,Tridymite,380, Aerosil,Dioxide, Silicon,G32, Quso,Quso G 32
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine
D015417 Hereditary Sensory and Motor Neuropathy A group of slowly progressive inherited disorders affecting motor and sensory peripheral nerves. Subtypes include HMSNs I-VII. HMSN I and II both refer to CHARCOT-MARIE-TOOTH DISEASE. HMSN III refers to hypertrophic neuropathy of infancy. HMSN IV refers to REFSUM DISEASE. HMSN V refers to a condition marked by a hereditary motor and sensory neuropathy associated with spastic paraplegia (see SPASTIC PARAPLEGIA, HEREDITARY). HMSN VI refers to HMSN associated with an inherited optic atrophy (OPTIC ATROPHIES, HEREDITARY), and HMSN VII refers to HMSN associated with retinitis pigmentosa. (From Adams et al., Principles of Neurology, 6th ed, p1343) Dejerine-Sottas Disease,HMSN,HMSN Type III,HMSN Type VII,Hereditary Motor and Sensory Neuropathies,Hereditary, Type III, Motor and Sensory Neuropathy,Hereditary, Type VII, Motor and Sensory Neuropathy,Neuropathies, Hereditary Motor and Sensory,CMT4f,Charcot-Marie-Tooth Disease, Demyelinating, Type 4f,Charcot-Marie-Tooth Disease, Type 3,Dejerine-Sottas Neuropathy,Dejerine-Sottas Syndrome,HMSN3,Herditary Sensory and Motor Neuropathy,Hereditary Motor and Sensory Neuropathy,Hereditary Motor and Sensory Neuropathy 3,Hereditary Motor and Sensory Neuropathy Type III,Hypertrophic Neuropathy of Dejerine-Sottas,Charcot Marie Tooth Disease, Type 3,Dejerine Sottas Disease,Dejerine Sottas Neuropathy,Dejerine Sottas Syndrome,Dejerine-Sottas Hypertrophic Neuropathy,Disease, Dejerine-Sottas,HMSN Type IIIs,HMSN Type VIIs,Hypertrophic Neuropathy of Dejerine Sottas,Neuropathy, Dejerine-Sottas,Syndrome, Dejerine-Sottas,Type VII, HMSN
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Cheng Xu, and Hannah E Dobson, and Mengjie Yu, and Wang Gong, and Xiaoqi Sun, and Kyung Soo Park, and Andrew Kennedy, and Xingwu Zhou, and Jin Xu, and Yao Xu, and Andrew W Tai, and Yu Leo Lei, and James J Moon
October 2020, Advanced therapeutics,
Cheng Xu, and Hannah E Dobson, and Mengjie Yu, and Wang Gong, and Xiaoqi Sun, and Kyung Soo Park, and Andrew Kennedy, and Xingwu Zhou, and Jin Xu, and Yao Xu, and Andrew W Tai, and Yu Leo Lei, and James J Moon
December 2020, ACS applied materials & interfaces,
Cheng Xu, and Hannah E Dobson, and Mengjie Yu, and Wang Gong, and Xiaoqi Sun, and Kyung Soo Park, and Andrew Kennedy, and Xingwu Zhou, and Jin Xu, and Yao Xu, and Andrew W Tai, and Yu Leo Lei, and James J Moon
January 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Cheng Xu, and Hannah E Dobson, and Mengjie Yu, and Wang Gong, and Xiaoqi Sun, and Kyung Soo Park, and Andrew Kennedy, and Xingwu Zhou, and Jin Xu, and Yao Xu, and Andrew W Tai, and Yu Leo Lei, and James J Moon
November 2019, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology,
Cheng Xu, and Hannah E Dobson, and Mengjie Yu, and Wang Gong, and Xiaoqi Sun, and Kyung Soo Park, and Andrew Kennedy, and Xingwu Zhou, and Jin Xu, and Yao Xu, and Andrew W Tai, and Yu Leo Lei, and James J Moon
November 2023, Signal transduction and targeted therapy,
Cheng Xu, and Hannah E Dobson, and Mengjie Yu, and Wang Gong, and Xiaoqi Sun, and Kyung Soo Park, and Andrew Kennedy, and Xingwu Zhou, and Jin Xu, and Yao Xu, and Andrew W Tai, and Yu Leo Lei, and James J Moon
May 2018, Journal of materials science. Materials in medicine,
Cheng Xu, and Hannah E Dobson, and Mengjie Yu, and Wang Gong, and Xiaoqi Sun, and Kyung Soo Park, and Andrew Kennedy, and Xingwu Zhou, and Jin Xu, and Yao Xu, and Andrew W Tai, and Yu Leo Lei, and James J Moon
April 2012, Chemical Society reviews,
Cheng Xu, and Hannah E Dobson, and Mengjie Yu, and Wang Gong, and Xiaoqi Sun, and Kyung Soo Park, and Andrew Kennedy, and Xingwu Zhou, and Jin Xu, and Yao Xu, and Andrew W Tai, and Yu Leo Lei, and James J Moon
January 2019, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology,
Cheng Xu, and Hannah E Dobson, and Mengjie Yu, and Wang Gong, and Xiaoqi Sun, and Kyung Soo Park, and Andrew Kennedy, and Xingwu Zhou, and Jin Xu, and Yao Xu, and Andrew W Tai, and Yu Leo Lei, and James J Moon
February 2019, Chemical communications (Cambridge, England),
Cheng Xu, and Hannah E Dobson, and Mengjie Yu, and Wang Gong, and Xiaoqi Sun, and Kyung Soo Park, and Andrew Kennedy, and Xingwu Zhou, and Jin Xu, and Yao Xu, and Andrew W Tai, and Yu Leo Lei, and James J Moon
October 2011, Accounts of chemical research,
Copied contents to your clipboard!